Prostate cancer (PCa) is the second most common cause of cancer‐related mortality in men
in the United States. The androgen receptor (AR) and the physiological pathways it …

The androgen receptor (AR) plays a predominant role in prostate cancer (PCa) pathology. It
consists of an N-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region (HR) …

Prostate cancer (PCa) accounted for over 300 000 deaths world-wide in 2018. Most of the
PCa deaths occurred due to the aggressive castration-resistant PCa (CRPC). Since the …

The androgen receptor (AR) is a transcription factor that has a pivotal role in the occurrence
and progression of prostate cancer. The AR is activated by androgens that bind to its ligand …

The androgen receptor (AR) is dominant in prostate cancer (PCa) pathology. Current
therapeutic agents for advanced PCa include androgen synthesis inhibitors and AR …

Androgens and androgen receptors (AR) play a pivotal role in expression of the male
phenotype. Several diseases, such as androgen insensitivity syndrome (AIS) and prostate …

Traditional endocrine therapy for prostate cancer (PCa) has been directed at suppression of
the androgen receptor (AR) signaling axis since Huggins et al. discovered that …

The androgen receptor (AR) plays an essential role in the growth and progression of
prostate cancer (CaP). Ligand-activated AR inside the nucleus binds to the androgen …

Prostate cancer (PCa) is the second leading cause of cancer death in men. Current research
findings suggest that the androgen receptor (AR) and its signaling pathway contribute …

Androgen receptor (AR) is closely associated with a group of hormone‐related diseases
including the cancers of prostate, breast, ovary, pancreas, etc and anabolic deficiencies …